Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B), while State Street SPDR S&P Biotech ETF trades at $154.13 (market cap $10.11B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 2.6× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SHY | XBI | |
|---|---|---|
Market Cap | $26.68B | $10.11B |
Volume | 4,077,691 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $83.18 | $169.55 |
52-Week Low | $81.05 | $104.99 |
Typical Hold Time | 63 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.175, up 0.02% on the day, amid a bearish technical signal driven by moving averages. The stock shows neutral oscillators but faces selling pressure from the ADX indicator. Recent corporate actions include dividends scheduled for late 2026, with payouts of $0.24-$0.25 per share. The broader bond market context, with rising yields, influences sentiment around short-term bond ETFs like SHY.
The outlook for SHY is cautious due to technical bearishness and macroeconomic headwinds from rising interest rates. Opportunities exist for income-focused investors via dividends, but risks include prolonged bond market volatility and Fed policy uncertainty. Investor sentiment remains mixed, balancing yield appeal against duration risk in a higher-rate environment.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
